Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse, John B. MD *,1; Carlson, Anders L. MD 2; Komatsu, Mitsuhisa MD 3; Mosenzon, Ofri MD 4; Rose, Ludger MD 5; Liang, Bo MD 6; Buchholtz, Kristine MD 6; Horio, Hiroshi MSc 7; Kadowaki, Takashi MD 8
Diabetes, Obesity & Metabolism.
20(12):2885-2893, December 2018.
(Format: HTML, PDF)